As part of its strategic direction of internationalisation and further expansion of business in global markets, JGL hosted a group of ophthalmologists from the Kingdom of Saudi Arabia. The visit included a tour of the sterile production facilities within the JGL Pharma Valley complex in Svilno and a scientific presentation on the topic of dry eye.
“The Middle East and the markets of South-east Asia have been key areas for expanding JGL’s B2B business for many years. We estimate that these markets have exceptional sales potential for part of our portfolio in strategic therapeutic groups of ophthalmology, nasal sprays and dermatology”, said Dunja Siuc Valković, Director of Global Business Development at JGL, adding that the company’s business in Saudi Arabia started in 2017 with the successful registration of the Vizol S product line.
“We have established a good relationship with our distribution partner and created preconditions for further expanding our cooperation. Despite the COVID-19 pandemic, the launch took place in the last quarter of 2020, and we have achieved sales of 450,000 units to date with a strong growth trend. Due to the region’s specific climate, the prevalence of dry eye in the local population is extremely high, over 30 per cent. That is why our Vizol S drops, as an innovative and technologically advanced treatment, are well received by prescribing doctors, as evidenced by the visit of the group of ophthalmologists. In Rijeka, we hosted 15 of them who, after visiting our production complex, were impressed by the highly sophisticated technology in JGL plants and the innovative solutions that we are continuously developing in the field of eye and nasal therapy”, concluded Siuc Valković.
JGL continues to strengthen its portfolio in this potent market. Along with the already present Vizol S, the launch of Aqua Maris Classic, Strong, and Baby nasal sprays is under way.